RxDoctor Payments Data

Carlos Vigil, DO

Internal Medicine · Rancho Cucamonga, CANPI 1366494015

Payments from drug & device makers

$203in general payments, 2019–2025

Across 12 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$88
  • Johnson & Johnson$37
  • Beckman Coulter, Inc.$31
  • Pfizer$19
  • Novo Nordisk$15
  • E.r. Squibb & Sons, L.L.C.$14

What the payments were for

  • Food & beverage$203100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$203 in reported general payments places this provider in the 50th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$257,272
Medicare patients
596
Services billed
2,247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban46$37,185
XareltoRivaroxaban42$36,829
JanuviaSitagliptin Phosphate16$11,480
FarxigaDapagliflozin Propanediol17$11,297
Tresiba Flextouch U-200Insulin Degludec19$10,609
OzempicSemaglutide11$10,568
TrulicityDulaglutide11$10,230
CreonLipase/Protease/Amylase13$9,136
BrilintaTicagrelor15$8,364
JardianceEmpagliflozin13$7,701
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$6,147
Nifedipine ErNifedipine43$2,247
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,142
Diclofenac Sodium36$2,004
Pantoprazole Sodium130$1,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$37,18546 claims
Johnson & JohnsonXarelto$37$36,82942 claims
Novo NordiskOzempic$15$10,56811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Rancho Cucamonga

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →